Evonik is one of the world's leading specialty chemicals companies. Profitable growth and a sustained increase in the value of the company form the heart of our strategy, which is supported by our owners, RAG-Stiftung (74.99 percent) and funds managed by CVC Capital Partners (25.01 percent). Our specialty chemicals activities focus on high-growth megatrends—especially health, nutrition, resource efficiency, and globalization—and our goal is to enter attractive future-oriented markets.

In 2011 Evonik’s roughly 33,000 employees generated sales of €14.5 billion and an operating result (EBITDA) of €2.8 billion. More than 70 percent of sales are generated outside Germany, providing convincing evidence that our business is global.